BACKGROUND: The potential drug-drug interaction (pDDI) increases as the number of concomitant medications increases. Patients with cardiovascular disorders are at higher risk for drug- drug interactions because of the types and number of drugs they receive. While drug interactions are reported to be common, there is no published report of the prevalence of such interactions among Indian cardiac patients. The aim of the present study was to identify the pattern of pDDI and document any observed interaction. It was also planned to evaluate the demography of patients and correlate it with the drug-drug interactions. METHOD: A prospective observational study from Oct 2007 to Apr 2008 was carried out in 'cardiology department' of a hospital in South India. Those patients who were taking at least two drugs and had a hospital stay of at least 48 hours were included in the study. The medications of the patients were analyzed for possible interactions. Factors associated with pDDI were studied. The actual interactions that were observed during the hospital stay in the study subjects were documented. RESULTS: A total of 812 patients were included in the study. 388 pDDIs were identified among 249 patients. The incidence of pDDI was 30.67%. The most common potential interactions were between aspirin & heparin (29.38%), and clopidogrel & heparin (7.21%). Drug classes most commonly involved were antiplatelets, anticoagulants and diuretics. Majority of interactions were of moderate severity, delayed onset, and pharmacodynamic in nature. Total 68 actual interactions were observed in the observed cases. CONCLUSION: The present study identified pDDIs and also documented interactions in cardiovascular patients. Factors which had correlation with adverse drug interactions were identified. This study highlights the need for screening prescriptions of cardiovascular patients for pDDIs and proactive monitoring of patients who have identified risk factors; this helps in detection and prevention of possible adverse drug interactions.
BACKGROUND: The potential drug-drug interaction (pDDI) increases as the number of concomitant medications increases. Patients with cardiovascular disorders are at higher risk for drug- drug interactions because of the types and number of drugs they receive. While drug interactions are reported to be common, there is no published report of the prevalence of such interactions among Indian cardiac patients. The aim of the present study was to identify the pattern of pDDI and document any observed interaction. It was also planned to evaluate the demography of patients and correlate it with the drug-drug interactions. METHOD: A prospective observational study from Oct 2007 to Apr 2008 was carried out in 'cardiology department' of a hospital in South India. Those patients who were taking at least two drugs and had a hospital stay of at least 48 hours were included in the study. The medications of the patients were analyzed for possible interactions. Factors associated with pDDI were studied. The actual interactions that were observed during the hospital stay in the study subjects were documented. RESULTS: A total of 812 patients were included in the study. 388 pDDIs were identified among 249 patients. The incidence of pDDI was 30.67%. The most common potential interactions were between aspirin & heparin (29.38%), and clopidogrel & heparin (7.21%). Drug classes most commonly involved were antiplatelets, anticoagulants and diuretics. Majority of interactions were of moderate severity, delayed onset, and pharmacodynamic in nature. Total 68 actual interactions were observed in the observed cases. CONCLUSION: The present study identified pDDIs and also documented interactions in cardiovascular patients. Factors which had correlation with adverse drug interactions were identified. This study highlights the need for screening prescriptions of cardiovascular patients for pDDIs and proactive monitoring of patients who have identified risk factors; this helps in detection and prevention of possible adverse drug interactions.
Authors: Matthijs L Becker; Marjon Kallewaard; Peter W J Caspers; Loes E Visser; Hubert G M Leufkens; Bruno H Ch Stricker Journal: Pharmacoepidemiol Drug Saf Date: 2007-06 Impact factor: 2.890
Authors: L L Leape; T A Brennan; N Laird; A G Lawthers; A R Localio; B A Barnes; L Hebert; J P Newhouse; P C Weiler; H Hiatt Journal: N Engl J Med Date: 1991-02-07 Impact factor: 91.245
Authors: Alexandra E Rätz Bravo; Lydia Tchambaz; Anita Krähenbühl-Melcher; Lorenzo Hess; Raymond G Schlienger; Stephan Krähenbühl Journal: Drug Saf Date: 2005 Impact factor: 5.606
Authors: Maysaa Mahmood; Daniel C Malone; Grant H Skrepnek; Jacob Abarca; Edward P Armstrong; John E Murphy; Amy J Grizzle; Yu Ko; Raymond L Woosley Journal: Am J Health Syst Pharm Date: 2007-07-15 Impact factor: 2.637
Authors: Devendra Saksena; Yugal K Mishra; S Muralidharan; Vivek Kanhere; Pankaj Srivastava; C P Srivastava Journal: Indian J Thorac Cardiovasc Surg Date: 2019-01-28
Authors: Prasanna R Deshpande; Raghuram Vantipalli; C H Chaitanya Lakshmi; E Jagadeswara Rao; Bishnu Regmi; Abdul Ahad; P Sharmila Nirojini Journal: J Pharm Bioallied Sci Date: 2015 Jul-Sep